Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

• Status: Not yet recruiting
• Trial end date: 2028-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy of oncolytic virus plus PD-1 inhibitor to Patients with Advanced Pancreatic Cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Immune Checkpoint Inhibitors

Criteria

Inclusion Criteria:

• Ability to understand and the willingness to sign a written informed consent document.

• Age ≥ 18 years and ≤ 80 years.

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

• Histologically or cytologically confirmed advanced pancreas adenocarcinoma.

• Patients who have received at least two lines of anti-tumor chemotherapy, or patients who have been unsuitable or unwilling to standard therapy.

• Locally advanced, or metastatic pancreatic cancer.

• Presence of at least of one measurable lesion in agreement to RECIST criteria.

• The expected survival ≥ 3 months.

• Adequate organ performance based on laboratory blood tests.

• Patients who are willing or able to comply with study procedures.

Exclusion Criteria:

• Pregnant or nursing women.

• Primary pancreatic cancer, or prior treatment with oncolytic virus and PD-1 inhibitor.

• The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas.

• Inflammation of the digestive tract, including pancreatitis, cholecystitis, cholangitis, etc.

• Severe and uncontrollable accompanying diseases that may affect protocol compliance or interfere with the interpretation of results.

• Allergic to study drugs.

• Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.